Press Releases

Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment

Download PDF

Appoints Randolph M. Johnson, Ph.D. as Executive Vice President of Clinical Development and Chief Development Officer to Lead FDA Process

LOS ANGELES, CA -- (Marketwired) -- 12/02/14 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a biotechnology company developing innovative regenerative therapies, has received a final report from Emergo Group, Inc. ("Emergo") that reviewed, classified and recommended Endonovo's strategy for gaining FDA 510K regulatory clearance of their proprietary bioelectronic technology for the treatment of urinary incontinence in women.

The Company also announced that Randolph M. Johnson, Ph.D. has been appointed by the Company as its Executive Vice President, Clinical Development and Chief Development Officer, effective immediately, to lead its device clinical product development and regulatory clearance.

Alan Collier, Chief Executive Officer and Chairman of Endonovo Therapeutics, commented, "Receiving the Emergo report and its recommendations is an important step and will help structure the best path to market for our proprietary device.

"We are particularly delighted to welcome Dr. Randolph Johnson to Endonovo at this key juncture in the Company's development. His over two decades experience in drug discovery and development, new drug delivery initiatives and research with Amgen, Roche and other firms will be beneficial as we develop and implement our FDA regulatory pathway."

"Dr. Johnson's expertise and abilities will greatly assist us in the development and ultimate commercialization of 'cell-free' therapeutics that can promote the regeneration of tissues without the injection of stem cells into the body, which would result in safer and more effective therapies, lower medical costs and improvement in the quality of life for many women experiencing urinary incontinence."

"I am thrilled to join Endonovo Therapeutics. Studies have demonstrated the ability of Endonovo's proprietary technology to potentially control the embryogenic development process of human cells," stated Dr. Johnson. "The possibility to develop new treatments and therapies that could transform medicine is an extremely attractive opportunity."

Previously Dr. Johnson was President and Chief Executive Officer of Innov8r Therapeutics, a Stanford University oncology startup. Prior, he was Chief of Technology Development and Vice President of Research at KAI Pharmaceuticals, Inc., where he led the discovery, engineering and early development of velcalcetide™, a novel therapeutic approach for the treatment of secondary hyperparathyroidism in hemodialysis patients. That discovery in part led to KAI's acquisition by Amgen (NASDAQ: AMGN) where he subsequently served as Scientific Executive Director. Dr. Johnson previously served at Roche Bioscience as Department Head of Molecular & Cellular Biochemistry, Center for Biological Research.

Dr. Johnson is a patented inventor named on 12 U.S. and international patents filed and/or issued, for therapeutic products for pain, drug delivery and treatment of inflammatory diseases. He has authored over 115 scientific publications, abstracts, and book chapters.

Dr. Johnson earned his Ph.D. in Biomedical Sciences-Pharmacology at University of South Carolina School of Medicine. He was a Postdoctoral Research Fellow and Research Assistant Professor, Department of Pharmacology at University of Virginia School of Medicine and received his M.A. in Biology and B.S. in Zoology at California State University Long Beach.

About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off-the-shelf, cell free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases using proprietary technology and biomolecules secreted from cells.

Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:
Mr. Steven Barnes
Vice President of Investor Relations
Endonovo Therapeutics, Inc.
Tel: 800-701-1223 Ext. 108

Source: Endonovo Therapeutics, Inc.